See the DrugPatentWatch profile for Keytruda
What safety risks have been reported for Keytruda (pembrolizumab)?
Keytruda’s main safety profile comes from immune system overactivity. Because pembrolizumab blocks PD-1, it can trigger immune-related side effects that can involve multiple organs. These can include inflammation of the lungs (pneumonitis), colon (colitis/diarrhea), liver (hepatitis), endocrine glands (such as thyroid problems, adrenal issues, or diabetes), skin reactions, and kidney inflammation, among other immune-related effects. [1]
Some patients also experience infusion-related reactions. The overall approach in prescribing and monitoring focuses on early recognition of immune-related toxicity and prompt treatment with steroids and/or holding or discontinuing Keytruda depending on severity. [1]
What side effects do patients ask about most (and what should they do)?
Common patient-relevant issues include fatigue and diarrhea, along with immune-related symptoms that can start gradually and may look like common illnesses at first. Patients are typically counseled to report symptoms such as:
- New or worsening cough or shortness of breath (possible pneumonitis)
- Severe or persistent diarrhea, blood in stool, or severe abdominal pain (possible colitis)
- Yellowing of the skin/eyes, dark urine, or right-sided abdominal discomfort (possible hepatitis)
- Severe headaches, vision changes, extreme thirst/urination, or major weight change (possible endocrine effects)
- Rash or skin blistering (immune skin reactions)
Clinicians manage these by grading severity and adjusting Keytruda treatment as needed, with urgent evaluation for concerning symptoms. [1]
How does Keytruda safety differ from traditional chemotherapy?
Keytruda is not chemotherapy, and its toxicity pattern is different. Instead of predictable chemo-related side effects (like low blood counts or nausea as the main issue), immune-related adverse events can occur at any time during treatment and sometimes after stopping. That makes monitoring and rapid response to new symptoms especially important. [1]
When do immune-related side effects tend to happen?
Immune-related adverse events can occur during treatment, and some may begin after treatment has stopped. The key safety principle is that clinicians monitor throughout therapy and patients are advised not to ignore new symptoms even if they arise later in the course. [1]
What are the key safety monitoring steps clinicians use?
Safety monitoring typically includes:
- Regular clinical assessment for new symptoms
- Periodic lab testing to detect liver, kidney, and endocrine abnormalities
- Treatment interruption and immunosuppression (commonly corticosteroids) when immune-related toxicity is suspected or confirmed, based on severity
The exact monitoring schedule and management plan depend on the cancer type, baseline organ function, and how far along a patient is in therapy. [1]
Can Keytruda be used with other cancer treatments safely?
Combination regimens can change the overall risk profile because immune toxicity can increase when Keytruda is used with other agents. The prescribing information and regimen-specific guidance drive decisions on patient selection, monitoring intensity, and how to manage toxicities. [1]
Where can I check the latest Keytruda safety label and warnings?
For the most current safety information, including warnings, precautions, and immune-related adverse event descriptions, use the Keytruda prescribing information and labeling on DrugPatentWatch.com (which links to key documents and updates). [2]
Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
[2] https://www.drugpatentwatch.com/